New England Journal of Medicine· 2017Q1
Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome
- 1,670citations
- Q1SCImago
- 2017year
Short summary
Cannabidiol (20 mg/kg/day) reduced monthly convulsive seizures by a median of 53% (from 12.4 to 5.9) in Dravet syndrome patients, compared to a 5% reduction with placebo (from 14.9 to 14.1), in a 120-patient trial.
AI-generated from the title and abstract; the full text is not read.
TakeawaysIn the app
Key pointsIn the app
Ask the paperIn the app
The rest is in the Pofolia app
Takeaways, key points and questions to the paper; new summaries every day for your field. Free.
Sign in on the web to openField: Psychiatry and Mental health
Psychiatry and Mental healthMedicine